21254-24-0 Usage
General Description
5-AMINO-1-ISOPROPYL-1H-PYRAZOLE-4-CARBOXAMIDE, also known as A-3656, is a chemical compound with the molecular formula C8H14N4O. It is a derivative of pyrazole and contains an amino group and an isopropyl group attached to the pyrazole ring. 5-AMINO-1-ISOPROPYL-1H-PYRAZOLE-4-CARBOXAMIDE is commonly used in pharmaceutical research and drug development as a building block in the synthesis of various bioactive molecules. It has shown potential as an inhibitor of certain enzymes and has been studied for its potential therapeutic applications in the treatment of various diseases. Additionally, it has been investigated for its anti-inflammatory and anti-cancer properties.
Check Digit Verification of cas no
The CAS Registry Mumber 21254-24-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,1,2,5 and 4 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 21254-24:
(7*2)+(6*1)+(5*2)+(4*5)+(3*4)+(2*2)+(1*4)=70
70 % 10 = 0
So 21254-24-0 is a valid CAS Registry Number.
21254-24-0Relevant articles and documents
SUBSTITUTED METHYL PYRAZOLOPYRIMIDINONE AND METHYL IMIDAZOPYRAZINONE COMPOUNDS AS PDE1 INHIBITORS
-
Paragraph 0472, (2019/06/20)
A chemical entity of Formula (I) or Formula (II): wherein Ra, Rb, Re, and Rf have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in
TRICYCLIC DERIVATIVE
-
Paragraph 0177; 0180, (2016/04/20)
Disclosed are compounds useful as inhibitors of phosphodiesterase 1 (PDE1), compositions thereof, and methods of using the same.
AMINO-HETEROCYCLIC COMPOUNDS
-
Page/Page column 17, (2010/08/07)
The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.
